查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908695

癌症免疫疗法市场规模、份额和趋势分析报告：按产品、应用、分销管道、最终用途、地区和细分市场预测（2026-2033 年）

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Immunomodulators), By Application, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症免疫疗法市场概况

全球癌症免疫疗法市场预计到 2025 年将价值 1,532.7 亿美元，预计到 2033 年将达到 3,058 亿美元。

预计从2026年到2033年，该市场将以9.02%的复合年增长率成长。癌症发生率的上升是推动市场成长的关键因素。

根据《美国癌症协会日誌，预计到2024年，美国将新增约200万例癌症病例，并有611,720例癌症死亡病例。製药公司研发活动的增加、技术的进步以及新药的问世预计将推动预测期内癌症免疫疗法产业的成长。癌症发生率的上升正在推动癌症免疫疗法市场的需求。根据国际癌症研究机构（IARC）的估计，2020年全球确诊癌症病例约1,929万例，预计到2030年将增加至2,458万例。人口疾病负担的显着增加预计将推动市场成长。

预计在预测期内，新型免疫疗法的核准不断增加将推动市场成长。例如，2024年12月，Astra Zeneca的免疫疗法Imfinzi（Durvalumab）成为首个也是目前唯一核准治疗铂类化疗和放射线治疗后病情未进展的局限期小细胞肺癌（LS-SCLC）成人患者的治疗方法。同样，患者对皮下给药方式的偏好日益增长也推动了市场成长。 2024年9月，FDA核准了TECENTRIQ Hybrezza，这是首个皮下注射的PD-(L)1抑制剂，标誌着癌症免疫疗法领域的重大进展。该製剂为患者提供了更快捷的治疗选择（7分钟，而静脉注射则需要30-60分钟），同时保持了与静脉注射注射相当的安全性和有效性。

主要企业的多项策略措施预计也将有助于推动市场需求。例如，2023年9月，Imathys与Moderna达成策略合作，共同开发肿瘤药物。该合作包括评估Imathys的PRAME203 TCRT与Moderna的MARTE mRNA癌症疫苗的联合治疗。此外，2023年8月，FBD Biologics与上海復宏汉霖生物技术有限公司达成策略合作，共同推动新型免疫疗法的研发。这些进展正在推动市场成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章 癌症免疫疗法市场变数、趋势与范围

  • 市场谱系展望
    • 母市场展望
    • 相关及配套市场展望
  • 市场动态
  • 癌症免疫疗法市场分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析

第四章 癌症免疫疗法市场：产品估算与趋势分析

  • 按产品分類的市场份额（2025 年和 2033 年）
  • 全球癌症免疫疗法市场：产品展望
  • 市场规模、预测与趋势分析（2021-2033）
    • 单株抗体
    • 免疫调节剂
    • 溶瘤病毒疗法和癌症疫苗

第五章 癌症免疫疗法市场：按应用分類的估计和趋势分析

  • 按应用领域分類的市场份额（2025 年和 2033 年）
  • 全球癌症免疫疗法市场：按应用领域分類的展望
  • 市场规模、预测与趋势分析（2021-2033）
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 恶性黑色素瘤
    • 摄护腺癌
    • 头颈癌
    • 卵巢癌
    • 胰臟癌
    • 其他的

第六章 癌症免疫疗法市场：按分销管道分類的估算和趋势分析

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 全球癌症免疫疗法市场：分销前景
  • 以下市场规模、预测与趋势分析（2021-2033）：
    • 医院药房
    • 零售药房
    • 网路药房

第七章 癌症免疫疗法市场：依最终用途分類的估算与趋势分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 全球癌症免疫疗法市场：按最终用途分類的展望
  • 市场规模、预测与趋势分析（2021-2033）
    • 医院和诊所
    • 癌症研究中心
    • 其他的

第八章 癌症免疫疗法市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 全球市场概览（按地区划分）
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 对主要市场参与企业近期趋势和影响的分析
  • 公司/竞争格局分类
  • 供应商概况
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2025
    • Pfizer Inc.
    • AstraZeneca
    • Merck &Co., Inc
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Lilly
    • Johnson &Johnson Services, Inc
    • Immunocore, Ltd
Product Code: GVR-1-68038-693-6

Cancer Immunotherapy Market Summary

The global cancer immunotherapy market size was estimated at USD 153.27 billion in 2025 and is projected to reach USD 305.80 billion by 2033, growing at a CAGR of 9.02% from 2026 to 2033. The increasing prevalence of cancer is a significant factor driving market growth.

According to the American Cancer Society Journal, in the U.S., about 2 million new cancer cases and 611,720 cancer deaths are estimated to occur in the year 2024. Growing R&D activities by pharmaceutical companies, technological advancements, and the introduction of novel drugs are expected to drive the growth of the cancer immunotherapy industry in the forecast period. The increasing prevalence of cancer is boosting the demand for the cancer immunotherapy market. According to the International Agency for Research on Cancer (IARC) estimates, in the year 2020, there were about 19.29 million cancer cases, which is estimated to increase to 24.58 million cases by 2030. This significant increase in the disease burden on the population is expected to drive the market growth.

Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period. For instance, in December 2024, AstraZeneca's immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy. Similarly, the increasing patient preference for subcutaneous drug administration is fueling market growth. In September 2024, the FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, representing a significant breakthrough in cancer immunotherapy. This formulation offers patients a faster treatment option (7 minutes versus 30-60 minutes for intravenous infusion) while maintaining the same safety and efficacy as the intravenous version.

Various strategic initiatives undertaken by major players are also anticipated to facilitate the market demand. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop the Oncology Therapeutics. The collaboration includes an assessment of Immatics' investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. These aspects are driving the market growth.

Global Cancer Immunotherapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer immunotherapy market report based on product, application, distribution channel, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Clinics
  • Cancer Research Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Distribution
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing R&D activities by pharmaceutical companies
      • 3.2.1.3. Technological advancements and introduction of novel drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of side effects associated with the treatment
      • 3.2.2.2. High cost of therapy and unfavourable reimbursement scenario
  • 3.3. Cancer Immunotherapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Cancer Immunotherapy Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Monoclonal Antibodies
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Immunomodulators
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Cancer Immunotherapy Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Lung Cancer
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Breast Cancer
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Colorectal Cancer
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Melanoma
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Prostate Cancer
      • 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. Head and Neck Cancer
      • 5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. Ovarian Cancer
      • 5.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Pancreatic Cancer
      • 5.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

  • 6.1. Distribution Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Hospital Pharmacy
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Retail Pharmacy
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Online Pharmacy
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

  • 7.1. Distribution Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Cancer Immunotherapy Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Hospitals & Clinics
      • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.2. Cancer Research Centers
      • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Pfizer Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. AstraZeneca
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Merck & Co., Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Bristol-Myers Squibb Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Novartis AG
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Lilly
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Immunocore, Ltd
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 5 North America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 6 North America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 9 U.S. Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 10 U.S. Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 12 Canada Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 13 Canada Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 16 Mexico Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Germany Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 25 Germany Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 26 Germany Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 28 UK Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 29 UK Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 30 UK Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 31 UK Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 33 France Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 34 France Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 35 France Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Italy Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 37 Italy Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 38 Italy Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 39 Italy Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Spain Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 41 Spain Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 42 Spain Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 43 Spain Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 45 Denmark Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 48 Sweden Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 49 Sweden Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 50 Sweden Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 51 Sweden Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Norway Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 53 Norway Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 54 Norway Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 55 Norway Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 61 China Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 62 China Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 63 China Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 64 China Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Japan Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 66 Japan Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 67 Japan Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 68 Japan Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 69 India Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 70 India Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 71 India Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 72 India Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 73 South Korea Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 74 South Korea Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 75 South Korea Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 76 South Korea Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 77 Australia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 78 Australia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 79 Australia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 80 Australia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Thailand Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 82 Thailand Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 83 Thailand Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 84 Thailand Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Latin America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 86 Latin America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 87 Latin America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 88 Latin America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 89 Latin America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Brazil Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 91 Brazil Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 92 Brazil Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 93 Brazil Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 94 Argentina Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 95 Argentina Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 96 Argentina Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 97 Argentina Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 98 MEA Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 99 MEA Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 100 MEA Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 101 MEA Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 102 MEA Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 103 South Africa Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 104 South Africa Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 105 South Africa Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 106 South Africa Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 111 UAE Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 112 UAE Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 113 UAE Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 114 UAE Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 115 Kuwait Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 116 Kuwait Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 118 Kuwait Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Cancer Immunotherapy market: market outlook
  • Fig. 14 Cancer Immunotherapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Cancer Immunotherapy market driver impact
  • Fig. 20 Cancer Immunotherapy market restraint impact
  • Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
  • Fig. 22 Cancer Immunotherapy market: Product movement analysis
  • Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
  • Fig. 24 Monoclonal Antibodies market estimates and forecast, 2021 - 2033
  • Fig. 25 Immunomodulators market estimates and forecast, 2021 - 2033
  • Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2021 - 2033
  • Fig. 27 Cancer Immunotherapy Market: Application movement analysis
  • Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
  • Fig. 29 Lung Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 30 Breast Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 31 Colorectal Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 32 Melanoma market estimates and forecasts, 2021 - 2033
  • Fig. 33 Prostate Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 34 Head and Neck Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 35 Ovarian Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 36 Pancreatic Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 37 Others market estimates and forecasts, 2021 - 2033
  • Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
  • Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
  • Fig. 40 Hospital Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 41 Retail Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 42 Online Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 43 Cancer Immunotherapy market: End Use movement analysis
  • Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
  • Fig. 45 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 46 Cancer Research Centers market estimates and forecasts, 2021 - 2033
  • Fig. 47 Others market estimates and forecasts, 2021 - 2033
  • Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
  • Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
  • Fig. 50 Global Cancer Immunotherapy market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, by country
  • Fig. 62 North America
  • Fig. 63 North America market estimates and forecasts, 2021 - 2033
  • Fig. 64 U.S.
  • Fig. 65 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 66 Canada
  • Fig. 67 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 72 UK
  • Fig. 73 UK market estimates and forecasts, 2021 - 2033
  • Fig. 74 Germany
  • Fig. 75 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 76 France
  • Fig. 77 France market estimates and forecasts, 2021 - 2033
  • Fig. 78 Italy
  • Fig. 79 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 80 Spain
  • Fig. 81 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 82 Denmark
  • Fig. 83 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 84 Sweden
  • Fig. 85 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 86 Norway
  • Fig. 87 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 90 China
  • Fig. 91 China market estimates and forecasts, 2021 - 2033
  • Fig. 92 Japan
  • Fig. 93 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 94 India
  • Fig. 95 India market estimates and forecasts, 2021 - 2033
  • Fig. 96 Thailand
  • Fig. 97 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Korea
  • Fig. 99 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 100 Australia
  • Fig. 101 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 104 Brazil
  • Fig. 105 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 106 Argentina
  • Fig. 107 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 108 Middle East and Africa
  • Fig. 109 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 110 South Africa
  • Fig. 111 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 112 Saudi Arabia
  • Fig. 113 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 114 UAE
  • Fig. 115 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 116 Kuwait
  • Fig. 117 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 118 Market share of key market players- Cancer Immunotherapy market